Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan (JK-1201I) in Patients with Malignant Solid Tumor [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of the injectable PEGylated irinotecan JK-1201I in patients with malignant solid tumor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• Pegylated irinotecan (JK-1201I) (pegylated irinotecan)

Snippet

Sponsor: JenKem Technology Co., Ltd. | Conditions: Solid Tumor | Phase 1 | Status: COMPLETED